Sugi Predict

Sugi Predict / Compounds / SCHEMBL358090

SCHEMBL358090

SCHEMBL358090

COC(CN(C)C(=O)OCc1ccccc1)OC

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 4/20 0.49
▸ ABCB1 P08183 2/20 0.48
▸ MAPT P10636 2/20 0.46
▸ HPGD P15428 1/20 0.46
▸ CHRNB2 P17787 1/20 0.45
▸ CHRNB4 P30926 1/20 0.45
▸ CHRNA3 P32297 1/20 0.45
▸ CHRNA4 P43681 1/20 0.45
▸ NPC1 O15118 1/20 0.44
▸ KMT2A Q03164 2/20 0.44
▸ MAPK1 P28482 1/20 0.44
▸ L3MBTL1 Q9Y468 1/20 0.44
▸ SLC6A2 P23975 1/20 0.44
▸ SLC6A3 Q01959 1/20 0.44
▸ TDP1 Q9NUW8 1/20 0.44
▸ SIGMAR1 Q99720 1/20 0.42
▸ CCR6 P51684 1/20 0.41
▸ PAX8 Q06710 1/20 0.41
▸ MEN1 O00255 1/20 0.41
▸ LMNA P02545 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28147701 0.89 ABCB1 (0.44) ALDH1A1ABCB1MAPTHPGDCHRNB2
SCHEMBL13687217 0.84 ALDH1A1 (0.51) ALDH1A1ABCB1MAPTHPGDCHRNB2
SCHEMBL17184916 0.82 ABCB1 (0.49) ALDH1A1ABCB1MAPTHPGDCHRNB2
SCHEMBL19541343 0.82 ALDH1A1 (0.49) ALDH1A1ABCB1MAPTHPGDCHRNB2
SCHEMBL1850525 0.81 ALDH1A1 (0.45) ALDH1A1ABCB1MAPTHPGDNPC1
SCHEMBL17688549 0.81 ALDH1A1 (0.55) ALDH1A1ABCB1MAPTHPGDCHRNB2
SCHEMBL24115182 0.80 ALDH1A1 (0.58) ALDH1A1ABCB1MAPTHPGDNPC1
SCHEMBL7367495 0.80 ALDH1A1 (0.58) ALDH1A1ABCB1MAPTHPGDCHRNB2
SCHEMBL3982639 0.80 CTSL (0.58) ALDH1A1NPC1KMT2AMAPK1L3MBTL1
SCHEMBL7393237 0.79 CYP1A2 (0.53) ALDH1A1ABCB1MAPTHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250136550-A1 PROCESSES FOR PREPARING REVEFENACIN AND COMPOSITIONS COMPRISING THE SAME THERAVANCE BIOPHARMA R&D IP, LLC 2025-05-01 — — US disclosed
EP-4165023-A1 INHIBITORS OF APOL1 AND USE OF THE SAME Vertex Pharmaceuticals Incorporated (US) 2023-04-19 — — EP disclosed
CN-115867532-A Inhibitors of APOL1 and uses thereof 弗特克斯药品有限公司 2023-03-28 — — CN disclosed
US-20230014907-A1 INHIBITORS OF APOL1 AND METHODS OF USING SAME VERTEX PHARMACEUTICALS INCORPORATED 2023-01-19 — — US disclosed
WO-2021252849-A1 INHIBITORS OF APOL1 AND USE OF THE SAME VERTEX PHARMACEUTICALS INCORPORATED (US) 2021-12-16 — — WO disclosed
EP-2593429-B1 PROCESS FOR PREPARING A BIPHENYL-2-YLCARBAMIC ACID THERAVANCE BIOPHARMA R & D IP LLC (US) 2015-06-03 — — EP disclosed
EP-2593429-B1 PROCESS FOR PREPARING A BIPHENYL-2-YLCARBAMIC ACID THERAVANCE BIOPHARMA R & D IP LLC (US) 2015-06-03 — — EP disclosed
US-9035061-B2 Process for preparing a biphenyl-2-ylcarbamic acid THERAVANCE BIOPHARMA R&D IP, LLC (US) 2015-05-19 — — US disclosed
US-9035061-B2 Process for preparing a biphenyl-2-ylcarbamic acid THERAVANCE BIOPHARMA R&D IP, LLC (US) 2015-05-19 — — US disclosed
US-9035061-B2 Process for preparing a biphenyl-2-ylcarbamic acid THERAVANCE BIOPHARMA R&D IP, LLC (US) 2015-05-19 — — US disclosed
US-8754225-B2 Process for preparing a biphenyl-2-ylcarbamic acid THERAVANCE, INC. (US) 2014-06-17 — — US disclosed
US-8754225-B2 Process for preparing a biphenyl-2-ylcarbamic acid THERAVANCE, INC. (US) 2014-06-17 — — US disclosed
US-20140121378-A1 PROCESS FOR PREPARING A BIPHENYL-2-YLCARBAMIC ACID THERAVANCE, INC. (US) 2014-05-01 — — US disclosed
EP-2593429-A1 PROCESS FOR PREPARING A BIPHENYL-2-YLCARBAMIC ACID Theravance, Inc. (US) 2013-05-22 — — EP disclosed
CN-102958916-A Process for preparing biphenyl-2-ylcarbamic acid THERAVANCE INC 2013-03-06 — — CN disclosed
US-20120016130-A1 PROCESS FOR PREPARING A BIPHENYL-2-YLCARBAMIC ACID THERAVANCE BIOPHARMA R&D IP, LLC 2012-01-19 — — US disclosed
US-20120016130-A1 PROCESS FOR PREPARING A BIPHENYL-2-YLCARBAMIC ACID THERAVANCE BIOPHARMA R&D IP, LLC 2012-01-19 — — US disclosed
US-20120016130-A1 PROCESS FOR PREPARING A BIPHENYL-2-YLCARBAMIC ACID THERAVANCE BIOPHARMA R&D IP, LLC 2012-01-19 — — US disclosed
WO-2012009166-A1 PROCESS FOR PREPARING A BIPHENYL-2-YLCARBAMIC ACID THERAVANCE, INC. (US) 2012-01-19 — — WO disclosed
WO-2012009166-A1 PROCESS FOR PREPARING A BIPHENYL-2-YLCARBAMIC ACID THERAVANCE, INC. (US) 2012-01-19 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250136550-A1 PROCESSES FOR PREPARING REVEFENACIN AND COMPOSITIONS COMPRISING THE SAME CYP4B1, KDM4B, CYP3A4 ALDH1A1 648/4885ABCB1 1879/4885MAPT 3100/4885
US-20230014907-A1 INHIBITORS OF APOL1 AND METHODS OF USING SAME APOL1, APOB, NPC1L1 ALDH1A1 1965/4885ABCB1 503/4885MAPT 3499/4885
US-20140121378-A1 PROCESS FOR PREPARING A BIPHENYL-2-YLCARBAMIC ACID CYP4B1, KDM2B, CYP26B1 ALDH1A1 742/4885ABCB1 702/4885MAPT 4262/4885
US-20120016130-A1 PROCESS FOR PREPARING A BIPHENYL-2-YLCARBAMIC ACID CYP4B1, KDM2B, CYP26B1 ALDH1A1 742/4885ABCB1 702/4885MAPT 4262/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.